Last reviewed · How we verify
NCT04393155
COVID Cohort Study
trial testing COVID-19+ observational in COVID-19 in 16 participants. Terminated before completion.
20 January 2021
Quick facts
| Lead sponsor | University of Vermont |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 16 |
| Start date | 16 April 2020 |
| Primary completion | 20 January 2021 |
| Estimated completion | 25 January 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- COVID-19+ observational
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- Acute Respiratory Failure — all drugs for Acute Respiratory Failure →
Sponsor
University of Vermont
Who can join
18 and older, any sex, with COVID-19 or Acute Respiratory Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The novel SARS-CoV-2 virus has quickly spread worldwide, with substantial morbidity and mortality. There is very limited understanding of the short- and longer-term inflammatory/immunological and clinical course. However, the investigators expect survivors from severe COVID-19 to experience persistent functional impairments, as demonstrated in prior studies of patients with acute respiratory distress syndrome (ARDS) and other acute viral illnesses. Notably, however, few studies have ever investigated the biologic mechanisms underlying these functional impairments. Understanding these features of COVID-19 will improve the ability to design acute therapies and recovery-focused interventions. To address these knowledge gaps, the investigators propose a two-center, 225 patient longitudinal prospective cohort study of hospitalized COVID-19 patients with acute respiratory failure. Researchers will perform an in-depth evaluation of inflammatory/immunological biomarkers, and physical, pulmonary, and neuropsychological clinical outcomes during hospitalization, and over 3-, 6-, and 12-month follow-up.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04393155
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other University of Vermont trials
Trials by the same sponsor.
- NCT07495098 — Phase 1B Trial of Intratumoral Cisplatin for Stage IV Lung Cancer · Phase 1 · not yet recruiting
- NCT07440641 — RE-FIT (Remote Exercise for Physical Function in WTC Responders With Prostate Cancer) · NA · not yet recruiting
- NCT06993129 — A Multi-Site Hybrid Type I Effectiveness-Implementation Randomized Trial of an Emergency Care Action Plan for Infants Wi · NA · not yet recruiting
- NCT07383727 — Readiness to Change and the Implementation of Home Modifications for Adults Over 60 · NA · not yet recruiting
- NCT06670079 — Prolonged Exposure Therapy to Treat Posttraumatic Stress Disorder in Pregnant Patients · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04393155 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Vermont
- Last refreshed: 12 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04393155.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing